Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.91-0.82 (-9.39%)
At close: 04:00PM EST
7.93 +0.02 (+0.25%)
After hours: 07:29PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Hammer

Hammer

Previous Close8.73
Open8.50
Bid7.86 x 2900
Ask8.76 x 800
Day's Range7.85 - 8.59
52 Week Range7.85 - 33.55
Volume2,144,358
Avg. Volume2,203,722
Market Cap554.549M
Beta (5Y Monthly)1.61
PE Ratio (TTM)N/A
EPS (TTM)-12.82
Earnings DateFeb 21, 2022 - Feb 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.91
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BLUE

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • bluebird bio, Inc.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features our annual pharmaceutical pipeline, a fresh look at Barry Callebaut's chocolate operation, the buzz around RingCentral, and SAP, Subsea 7, and Just Eat Takeaway.
    Rating
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
  • Business Wire

    bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)

    CAMBRIDGE, Mass., January 18, 2022--bluebird bio, Inc. (NASDAQ: BLUE) today announced that the US Food and Drug Administration (FDA) has extended the review period for the biologics licensing applications (BLA) for its lentiviral vector gene therapies – betibeglogene autotemcel (beti-cel) for β-thalassemia and elivaldogene autotemcel (eli-cel) for cerebral adrenoleukodystrophy (CALD). The revised PDUFA goal dates for beti-cel and eli-cel are August 19, 2022 and September 16, 2022, respectively.

  • Motley Fool

    Why Bluebird Bio Stock Is Sinking This Week

    Shares of gene therapy company Bluebird Bio (NASDAQ: BLUE) fell by 10.7% through the first four full days of trading this week, according to data provided by S&P Global Market Intelligence. With two potential regulatory approvals and commercial launches coming down the pike later this year, Bluebird's most recent cash, cash equivalents, and marketable securities balance of approximately $442 million probably won't be sufficient to meet its short-term financial needs. On a positive note, Bluebird said it plans on exploring the sale for the priority review vouchers expected to be issued with the U.S. approvals of its gene therapies known as beti-cel and eli-cel, respectively.

  • American City Business Journals

    Post-split bluebird bio plans to launch 3 gene therapies in 2 years

    Following the spinout of its cancer business, bluebird bio Inc. is all in on gene therapy, with plans to launch three new drugs by the end of 2023.

Advertisement
Advertisement